戴維醫療(300314.SZ):一次性腔鏡用電動切割吻合器及組件正式獲得美國市場準入許可
格隆匯5月19日丨戴維醫療(300314.SZ)公佈,公司全資子公司寧波維爾凱迪醫療器械有限公司(“維爾凱迪”)於近日收到美國食品藥品管理局(“FDA”)的通知,維爾凱迪產品一次性腔鏡用電動切割吻合器及組件正式獲得美國市場準入許可。
維爾凱迪上述產品通過FDA的審核,標誌着該產品獲得了進入美國市場銷售的資質,對該產品在國際市場的銷售將起到推動作用。上述產品在美國等國際市場的實際銷售情況將受未來市場的推廣效果及國際市場政策環境變化、匯率波動等因素的影響,敬請廣大投資者謹慎投資,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.